0000899243-22-005213.txt : 20220208
0000899243-22-005213.hdr.sgml : 20220208
20220208160556
ACCESSION NUMBER: 0000899243-22-005213
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220204
FILED AS OF DATE: 20220208
DATE AS OF CHANGE: 20220208
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Brennan Aoife
CENTRAL INDEX KEY: 0001714563
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37566
FILM NUMBER: 22601613
MAIL ADDRESS:
STREET 1: 200 SIDNEY STREET, SUITE 320
STREET 2: C/O SYNLOGIC, INC.
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SYNLOGIC, INC.
CENTRAL INDEX KEY: 0001527599
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 261824804
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 301 BINNEY STREET
STREET 2: SUITE 402
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-401-9975
MAIL ADDRESS:
STREET 1: 301 BINNEY STREET
STREET 2: SUITE 402
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Mirna Therapeutics, Inc.
DATE OF NAME CHANGE: 20110809
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-02-04
0
0001527599
SYNLOGIC, INC.
SYBX
0001714563
Brennan Aoife
C/O SYNLOGIC, INC.
301 BINNEY STREET, SUITE 402
CAMBRIDGE
MA
02142
1
1
0
0
See Remarks
Common Stock
2022-02-04
4
A
0
106920
0.00
A
284237
D
Stock Option (right to buy)
1.95
2022-02-04
4
A
0
434160
0.00
A
2032-02-04
Common Stock
434160
434160
D
The shares of restricted stock were granted on February 4, 2022, and will vest beginning on April 1, 2022 (the "Vesting Start Date") in four equal annual installments on each anniversary of the Vesting Start Date, subject to the Reporting Person continuing to provide services to the Issuer as Chief Executive Officer through each such vesting date.
The option will vest and become exercisable in equal monthly installments for forty-eight months beginning on the grant date, which is February 4, 2022, subject to the Reporting Person continuing to provide services to the Issuer as Chief Executive Officer through each such vesting date.
President and Chief Executive Officer
/s/ Aoife Brennan
2022-02-08